SenesTech Launches Second Manufacturing Line in Flagstaff to Ensure Uninterrupted Supply

FLAGSTAFF, Ariz., June 13, 2017  — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that in an effort to ensure that the Company can meet the rapidly increasing demand for their innovative new rodent control technology, ContraPest, it has launched its second manufacturing line in Flagstaff. With the addition of this second line, the Company’s existing manufacturing capacity is expected to more than double.

Continue reading

C-PATH and CDISC Announce Public Review Period for Duchenne Therapeutic Area Standard

 The Clinical Data Interchange Standards Consortium (CDISC) and Critical Path Institute (C-Path) announce the availability of a Duchenne muscular dystrophy therapeutic area user guide (TAUG-DMD v1.0) for public review. The review period for the TAUG-DMD v1.0 began on May 8, 2017, and runs through July 6, 2017. Qualified researchers and clinicians are encouraged to review TAUG-DMD v1.0 and offer feedback.Continue reading